CN104688923A - Medicine used for treating insulin resistance - Google Patents
Medicine used for treating insulin resistance Download PDFInfo
- Publication number
- CN104688923A CN104688923A CN201310422381.8A CN201310422381A CN104688923A CN 104688923 A CN104688923 A CN 104688923A CN 201310422381 A CN201310422381 A CN 201310422381A CN 104688923 A CN104688923 A CN 104688923A
- Authority
- CN
- China
- Prior art keywords
- medicine
- glp
- diabetes
- group
- insulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a medicine used for treating insulin resistance. The medicine comprises following ingredients, by weight, 28.2 to 31.7% of potmarigold calendula flower and root, 22.7 to 26.5% of herba epimedii, 24.4 to 29.3% of Chinese wolfberry fruit, and 21.7 to 24.3% of codonopsis pilosula. The medicine is prepared via a common preparation method; and the preparation method comprises following steps: the ingredients above are smashed and mixed, and an obtained mixture is made into powder or any other pharmaceutical dosage forms. It is confirmed by experiments that: the medicine is capable of increasing content of glucagon-like peptide 1 effectively, so that blood glucose level of diabetic rats can be reduced effectively.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of insulin resistant
Background technology
Diabetes (diabetes) be multiple virulence factor act on body cause hypoinsulinism, insulin resistant etc. and cause a series of metabolism disorder syndrome such as sugar, protein, fat, water and eletrolytes, be main feature clinically with hyperglycemia.The overall prevalence of the current diabetes of China reaches 9.7%.The same period prediabetes prevalence up to 15.5%.The reckoning made according to survey result shows China's total patient of diabetes patient number and reaches more than 9,000 2 hundred ten thousand, and prediabetes number reaches more than 100,000,000 4 thousand 8 hundred ten thousand.
Oral glucose to the facilitation of insulin secretion apparently higher than intravenous injection, this extra effect is called as " secretin's effect ", further research confirms, the insulin that this " secretin's effect " produces accounts for more than 50% of the rear insulin total amount of feed.Type 2 diabetes mellitus patient secretin effect is gone down, and this prompting, secretin's system exception may be one of pathogenesis of type 2 diabetes mellitus.
Along with the development of Cytobiology and molecular biology, the veil that secretin this layer is mysterious is slowly opened, and research confirms, secretin is a kind of Entero hormone in human body, on the feed, this parahormone can promote insulin secretion, plays concentration of glucose dependency blood sugar reducing function.The main GLP-1 of secretin and glucose-dependent insulinotropic peptide (GIP) composition, wherein GLP-1 plays a part even more important in the developing of type 2 diabetes mellitus.
GLP-1 is by glucagon antigen gene expressed, in alpha Cell of islet, the main expression product of glucagon protogene is glucagon, and in the L cell of intestinal mucosa, Proglucagon is cut into the peptide sequence of its c-terminus by prohormone converting Enzyme (PC1), i.e. GLP-1.GLP-1 has 2 kinds of biologically active forms, and be respectively GLP-1 (7-37) and GLP-1 (7-36) amide, both only has an aminoacid sequence difference, and the circulation of GLP-1 about 80% is active in GLP-1 (7-36) amide.Research confirms, and secretin promotes islet β cell insulin in concentration of glucose dependency mode, and reduces alpha Cell of islet secretion glucagon (glucagon), thus reduces blood glucose.Normal person is after dining, and secretin starts secretion, and then promotes insulin secretion, to reduce the fluctuation of post-prandial glycemia.But for type 2 diabetes mellitus patient, its " secretin's effect " is impaired, main manifestations is that after having meal, GLP-1 concentration elevation amplitude calibration ordinary person reduces to some extent, but it promotes that insulin secretion and hypoglycemic effect there is no obviously impaired, therefore GLP-1 and analog thereof can as important target spots of type 2 diabetes mellitus treatment.GLP-1 plays blood sugar reducing function mainly through following several respects.The effect GLP-1 that GLP-1 has protection β cell can act on beta Cell of islet; promote the transcribing of insulin gene, the synthesis of insulin and secretion [1]; and propagation and the differentiation of beta Cell of islet can be stimulated, suppress islet beta-cell apoptosis, increase beta Cell of islet quantity.In addition, GLP-1 also can act on alpha Cell of islet, consumingly the release of glucagon suppression, and acts on delta Cell of islet, the secretion of growth promoting effects chalone, and somatostatin can be used as again the secretion that paracrine hormone participates in glucagon suppression.Research proves, GLP-1 improves the blood glucose situation of type 2 diabetes mellitus animal model or patient significantly by number of mechanisms, wherein promote regeneration and the reparation of beta Cell of islet, the effect increasing beta Cell of islet quantity is particularly remarkable, and this is that the treatment of type 2 diabetes mellitus provides an extraordinary prospect.GLP-1 has concentration of glucose dependency blood sugar reducing function as a kind of Entero hormone, GLP-1 is just released into blood under the stimulation of nutrient substance particularly carbohydrate, its promoting insulin secretion is concentration of glucose dependency, the type 2 diabetes mellitus patient to 10 routine poor blood glucose control such as Nauck is studied, and patient GLP-1 or placebo is given respectively under fasted conditions, result shows, patient is after infusion GLP-1, its insulin and C peptide level significantly increase, Plasma Glucagon Level significantly reduces, fasting blood glucose level becomes normally after 4 hours.After blood sugar level is normal, although still continuous infusion GLP-1, the insulin level of patient can not raise again, and blood sugar level also remains stable, declines no longer further.This illustrates that GLP-1 has concentration of glucose dependency blood sugar reducing function, and namely only when blood sugar level raises, GLP-1 just plays blood sugar reducing function, and when blood sugar level is normal, then it can not be made to reduce further.This concentration of glucose dependency blood sugar lowering characteristic of GLP-1 is basis and the guarantee of its clinical practice safety, thus eliminates people may cause patient's severe hypoglycemia worry to existing Remedies for diabetes and scheme.GLP-1 has slimming effect.Have report research display, accepting after GLP-1 treats 6 weeks, the weight average participating in 20 routine type 2 diabetes mellitus patients of research alleviates 1.9kg.Researcher is thought, GLP-1 produces by number of ways to reduce the effect of body weight, comprises and suppresses gastrointestinal motility and gastric secretion, appetite-suppressing and ingesting, and delays gastric content emptying.In addition, GLP-1 also can act on central nervous system's (particularly hypothalamus), thus makes human body produce feeling of repletion and appetite decline.In addition, GLP-1 also has many other biological characteristics and function, and such as, GLP-1 may play blood fat reducing, hypotensive effect, thus produces protective effect to cardiovascular system; It also strengthens learning and memory function, neuroprotective by acting on maincenter.
The medicine that this patent is applied for is with pure natural plant Calendula officinalis, Herba Epimedii, Fructus Lycii, a kind of medicine for the treatment of insulin resistant that Radix Codonopsis hybrid process is refined, special curative effect is had to the diabetes caused by GLP-1 abnormal (insulin resistant), can raise the content of GLP-1D, described Calendula officinalis accounts for the percentage ratio of the gross weight of described medicine at 28.2%-31.7%; Described Herba Epimedii accounts for the percentage ratio of the gross weight of described medicine between 22.7%-26.5%, described Fructus Lycii accounts for the percentage ratio of the gross weight of described medicine between 24.4%-29.3%, and described Radix Codonopsis accounts for the percentage ratio of the gross weight of described medicine between 21.7%-24.3%.
Summary of the invention
1 technical problem to be solved by this invention is to provide a kind of medicine for the treatment of insulin resistant, containing 4 taste Chinese medicines.
2 technical problems to be solved by this invention are also: provide a kind of medicine for the treatment of insulin resistant.
3 these medicines effectively can treat diabetes and without any side effects.
Accompanying drawing explanation
What figure 1 shows that this patent applies for can raise diabetes rat blood GLP-1 content to the medicative medicine of insulin resistant, and in figure, a is Normal group, b group, c group, d group, e group, and f group and g group are diabetes blank group and different medication group.
A. normal blank contrast
B. diabetes blank
C. diabetes this patent apply for the medicative medicine of insulin resistant
D. the alone Calendula officinalis of diabetes
E. the alone Herba Epimedii of diabetes
F. the alone Fructus Lycii of diabetes
G. the alone Radix Codonopsis of diabetes
What figure 2 shows that this patent applies for can blood glucose in diabetic rats content to the medicative medicine of insulin resistant, and in figure, a is Normal group, b group, c group, d group, e group, and f group and g group are diabetes blank group and different medication group.
A. normal blank contrast
B. diabetes blank
C. diabetes this patent apply for the medicative medicine of insulin resistant
D. the alone Calendula officinalis of diabetes
E. the alone Herba Epimedii of diabetes
F. the alone Fructus Lycii of diabetes
G. the alone Radix Codonopsis of diabetes.
Claims (1)
1. treat a medicine for insulin resistant, it is characterized in that: described this medicine by Calendula officinalis, Herba Epimedii, Fructus Lycii, Radix Codonopsis form, wherein, described Calendula officinalis accounts for the percentage ratio of the gross weight of described medicine at 28.2%-31.7%; Described Herba Epimedii accounts for the percentage ratio of the gross weight of described medicine between 22.7%-26.5%, described Fructus Lycii accounts for the percentage ratio of the gross weight of described medicine between 24.4%-29.3%, and described Radix Codonopsis accounts for the percentage ratio of the gross weight of described medicine between 21.7%-24.3%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310422381.8A CN104688923A (en) | 2013-09-09 | 2013-09-09 | Medicine used for treating insulin resistance |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310422381.8A CN104688923A (en) | 2013-09-09 | 2013-09-09 | Medicine used for treating insulin resistance |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104688923A true CN104688923A (en) | 2015-06-10 |
Family
ID=53336747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310422381.8A Pending CN104688923A (en) | 2013-09-09 | 2013-09-09 | Medicine used for treating insulin resistance |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104688923A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101690778A (en) * | 2009-09-15 | 2010-04-07 | 上海和臣医药工程有限公司 | Chinese medicinal preparation for treating insulin resistance symptoms and preparation method thereof |
| CN102114185A (en) * | 2011-03-02 | 2011-07-06 | 山西省中医药研究院 | Medicament for treating insulin resistance of type 2 diabetes |
-
2013
- 2013-09-09 CN CN201310422381.8A patent/CN104688923A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101690778A (en) * | 2009-09-15 | 2010-04-07 | 上海和臣医药工程有限公司 | Chinese medicinal preparation for treating insulin resistance symptoms and preparation method thereof |
| CN102114185A (en) * | 2011-03-02 | 2011-07-06 | 山西省中医药研究院 | Medicament for treating insulin resistance of type 2 diabetes |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1997007814A1 (en) | Method and composition for enhanced parenteral nutrition | |
| CN105396126A (en) | Combination Of An Insulin And A GLP-1 Agonist | |
| CN105473155A (en) | Insulin glargine/lixisenatide fixed ratio formulation | |
| CN102603886B (en) | Mutant fibroblast growth factor and use thereof in treating endocrine diseases | |
| CN106279400A (en) | Design of P8 incretin peptide and application thereof | |
| CN102670661A (en) | Drug for stimulating glucagon-like peptide 1 (GLP-1) secretion | |
| CN104257696B (en) | A kind of steady sugar yeast bacterium powder of hypoglycemic and its preparation method and application | |
| WO2006126673A1 (en) | Combined drug for treating diabetes | |
| CN107952064A (en) | Pharmaceutical preparation containing polyethylene glycol Luo Saina peptides and preparation method thereof | |
| CN101003574B (en) | Recombined expression of peptide for lowering blood sugar in long acting, and application in medication for treating diabetes | |
| CN105250335A (en) | Methods for treating glucose metabolic disorders | |
| CN106519016A (en) | Design and application of blood glucose reducing and lipid regulating peptide Progly | |
| RU2694527C1 (en) | Combination for regenerative therapy of type 1 diabetes mellitus | |
| US20210052703A1 (en) | Glp-1 composition for treating obesity and weight management | |
| CN112057619A (en) | A pharmaceutical composition with blood sugar lowering effect | |
| CN1824224A (en) | 'Coptis-amonum' sugar reducing compound ready prepared Chinese medicinal capsule | |
| CN101642562A (en) | Preparation method of pharmaceutical preparation and injection of exenatide acetate | |
| CN103055176B (en) | Traditional Chinese medicine for treating diabetes mellitus and preparation method thereof | |
| CN104688923A (en) | Medicine used for treating insulin resistance | |
| Chung et al. | Spontaneous Hypoglycemia due to Insulin Antibody after Insulin Treatment of Diabetic Ketoacidosis. | |
| CN103566354A (en) | Pharmaceutical composition containing derivatives of GLP-1 analogue or medicinal salts thereof | |
| CN107669860A (en) | A kind of Chinese medicine composition and its application with blood sugar reducing function | |
| US20120269911A1 (en) | Compositions and Method for Enhancing Insulin Activity | |
| US20030118663A1 (en) | Method and composition for treating diabetes | |
| CN103007254A (en) | Application of glucagon-like peptide-1 in preparing medicament for treating 1-type diabetes mellitus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150610 |
|
| WD01 | Invention patent application deemed withdrawn after publication |